Halozyme Therapeutics reported 16.12 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
Acadia Pharmaceuticals 9.52 1.81 Sep/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Alnylam Pharmaceuticals 13.17 62.47 Sep/2026
Amarin 91.05 88.3 Jun/2023
Amgen 18.6 0.53 Sep/2026
Baxter International 20.35 131.6 Sep/2026
Cara Therapeutics 0.49 27.28 Mar/2026
Eli Lilly 64.5 31.61 Sep/2026
Halozyme Therapeutics 16.12 3.61 Sep/2026
Intrexon 7.54 221.44 Dec/2021
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
MannKind 201.15 102.55 Mar/2026
Pfizer 15.2 3.72 Sep/2026
Rigel Pharmaceuticals 8.61 8.4 Mar/2025
United Therapeutics 19.41 0.26 Sep/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023